U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C8H14NO.C6H5O3S
Molecular Weight 297.37
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FURTRETHONIUM BESYLATE

SMILES

C[N+](C)(C)CC1=CC=CO1.[O-]S(=O)(=O)C2=CC=CC=C2

InChI

InChIKey=IVNIBHOEODRCPK-UHFFFAOYSA-M
InChI=1S/C8H14NO.C6H6O3S/c1-9(2,3)7-8-5-4-6-10-8;7-10(8,9)6-4-2-1-3-5-6/h4-6H,7H2,1-3H3;1-5H,(H,7,8,9)/q+1;/p-1

HIDE SMILES / InChI

Molecular Formula C6H5O3S
Molecular Weight 157.167
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C8H14NO
Molecular Weight 140.2029
Charge 1
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

FURTRETHONIUM is an agonist of muscarinic acetylcholine receptors. It was used for the treatment of glaucoma.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Furmethide

Approved Use

Furtrethonum is a parasympathomimetic drug used for the treatment of glaucoma
Doses

Doses

DosePopulationAdverse events​
10 % 1 times / day multiple, ophthalmic
Dose: 10 %, 1 times / day
Route: ophthalmic
Route: multiple
Dose: 10 %, 1 times / day
Sources:
unhealthy
n = 21
Health Status: unhealthy
Condition: glaucoma
Population Size: 21
Sources:
Disc. AE: Dacryostenosis acquired...
AEs leading to
discontinuation/dose reduction:
Dacryostenosis acquired (71%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Dacryostenosis acquired 71%
Disc. AE
10 % 1 times / day multiple, ophthalmic
Dose: 10 %, 1 times / day
Route: ophthalmic
Route: multiple
Dose: 10 %, 1 times / day
Sources:
unhealthy
n = 21
Health Status: unhealthy
Condition: glaucoma
Population Size: 21
Sources:
PubMed

PubMed

TitleDatePubMed
Further studies on the use of furmethide in the treatment of glaucoma.
1946 Apr
The use of furmethide in comparison with pilocarpine and eserine for the treatment of glaucoma.
1947 Aug
Glaucoma treatment by furnethide and diisopropylfluorophosphate.
1949 Jul
Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors.
1997 Jul
Patents

Patents

Substance Class Chemical
Created
by admin
on Sat Dec 16 09:08:41 UTC 2023
Edited
by admin
on Sat Dec 16 09:08:41 UTC 2023
Record UNII
EGN9KOM72T
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FURTRETHONIUM BESYLATE
Common Name English
FURTRETHONIUM BENZENESULFONATE [MI]
Common Name English
BENZAMON
Brand Name English
FURFURYLTRIMETHYLAMMONIUM BENZENESULFONATE
Systematic Name English
2-FURANMETHANAMINIUM, N,N,N-TRIMETHYL-, BENZENESULFONATE (1:1)
Systematic Name English
TRIMETHYLFURFURYLAMMONIUM BENZENESULFONATE
Systematic Name English
FURTRETHONIUM BESILATE
Common Name English
2-FURANMETHANAMINIUM, N,N,N-TRIMETHYL-, BENZENESULFONATE
Systematic Name English
FURTRETHONIUM BENZENESULFONATE
MI  
Common Name English
Code System Code Type Description
MERCK INDEX
m5611
Created by admin on Sat Dec 16 09:08:41 UTC 2023 , Edited by admin on Sat Dec 16 09:08:41 UTC 2023
PRIMARY
FDA UNII
EGN9KOM72T
Created by admin on Sat Dec 16 09:08:41 UTC 2023 , Edited by admin on Sat Dec 16 09:08:41 UTC 2023
PRIMARY
CAS
3481-26-3
Created by admin on Sat Dec 16 09:08:41 UTC 2023 , Edited by admin on Sat Dec 16 09:08:41 UTC 2023
PRIMARY
PUBCHEM
15692623
Created by admin on Sat Dec 16 09:08:41 UTC 2023 , Edited by admin on Sat Dec 16 09:08:41 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY